AVEO Pharmaceuticals Granted Patent For Unique Genetic Screen To Identify Novel Cancer Drug Targets

AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, tannounced that on May 13, 2008, the United States Patent and Trademark Office granted U.S. Patent No. 7,371,515 covering AVEO’s Mammalian Second Site Suppressor (MaSS) screen technology for identifying small molecule and antibody targets functionally relevant to cancer cell proliferation and survival.

More: continued here

Filed under: Pharma Industry on June 1st, 2008